Spatial Analysis of FAP Gene Expression in Breast Cancer.

IF 2.5 4区 医学 Q3 ONCOLOGY
Liubov A Tashireva, Evgeniya S Grigoryeva, Ivan A Patskan, Anna Yu Kalinchuk, Roman V Zelchan
{"title":"Spatial Analysis of FAP Gene Expression in Breast Cancer.","authors":"Liubov A Tashireva, Evgeniya S Grigoryeva, Ivan A Patskan, Anna Yu Kalinchuk, Roman V Zelchan","doi":"10.2174/0115680096433584260407101537","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Fibroblast Activation Protein (FAP) is a key marker of Cancer-Associated Fibroblasts (CAFs) and a promising target for cancer theranostics. However, its expression in both stromal and tumor cells complicates therapeutic strategies.</p><p><strong>Methods: </strong>This study employed spatial transcriptomics to analyze FAP gene expression patterns in luminal breast cancer, revealing distinct molecular profiles in FAP+ stromal cells, FAP+ tumor cells, and tumor cells proximal to FAP+ stroma.</p><p><strong>Results: </strong>FAP+ stromal cells exhibited upregulation of Extracellular Matrix (ECM) remodeling genes (COL1A1, MMP2, TIMP2), secreted factors (CXCL12, POSTN), and immune modulators (CD276), confirming their role in desmoplasia and immunosuppression. In contrast, FAP+ tumor cells showed limited transcriptional changes but elevated POSTN, CD24, and EPCAM, suggesting roles in immune evasion and epithelial plasticity.</p><p><strong>Discussion: </strong>Spatial analysis revealed that tumor cells within 700 μm of FAP+ stroma displayed an aggressive phenotype, marked by ECM degradation (MMP14, COL6A1), mesenchymal markers (VIM), and immune suppression (HLA-DRA, CD276). Conversely, distal tumor cells exhibited metabolic adaptations (ACADSB, SCD) and survival mechanisms (SQSTM1, NUPR1), potentially conferring resistance to therapy.</p><p><strong>Conclusion: </strong>This spatial transcriptomics study elucidates the complex and context-dependent roles of FAP in luminal breast cancer, revealing distinct molecular programs driven by its cellular source and spatial location. We demonstrate that FAP+ CAFs are the primary architects of a profoundly immunosuppressive and pro-fibrotic tumor microenvironment, characterized by extensive ECM remodeling and secretion of CXCL12 and CD276. Furthermore, we identify a novel, aggressive tumor cell subpopulation defined by its proximity to FAP+ stroma, exhibiting a hybrid phenotype with features of ECM degradation, mesenchymal transition, and immune suppression.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096433584260407101537","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Fibroblast Activation Protein (FAP) is a key marker of Cancer-Associated Fibroblasts (CAFs) and a promising target for cancer theranostics. However, its expression in both stromal and tumor cells complicates therapeutic strategies.

Methods: This study employed spatial transcriptomics to analyze FAP gene expression patterns in luminal breast cancer, revealing distinct molecular profiles in FAP+ stromal cells, FAP+ tumor cells, and tumor cells proximal to FAP+ stroma.

Results: FAP+ stromal cells exhibited upregulation of Extracellular Matrix (ECM) remodeling genes (COL1A1, MMP2, TIMP2), secreted factors (CXCL12, POSTN), and immune modulators (CD276), confirming their role in desmoplasia and immunosuppression. In contrast, FAP+ tumor cells showed limited transcriptional changes but elevated POSTN, CD24, and EPCAM, suggesting roles in immune evasion and epithelial plasticity.

Discussion: Spatial analysis revealed that tumor cells within 700 μm of FAP+ stroma displayed an aggressive phenotype, marked by ECM degradation (MMP14, COL6A1), mesenchymal markers (VIM), and immune suppression (HLA-DRA, CD276). Conversely, distal tumor cells exhibited metabolic adaptations (ACADSB, SCD) and survival mechanisms (SQSTM1, NUPR1), potentially conferring resistance to therapy.

Conclusion: This spatial transcriptomics study elucidates the complex and context-dependent roles of FAP in luminal breast cancer, revealing distinct molecular programs driven by its cellular source and spatial location. We demonstrate that FAP+ CAFs are the primary architects of a profoundly immunosuppressive and pro-fibrotic tumor microenvironment, characterized by extensive ECM remodeling and secretion of CXCL12 and CD276. Furthermore, we identify a novel, aggressive tumor cell subpopulation defined by its proximity to FAP+ stroma, exhibiting a hybrid phenotype with features of ECM degradation, mesenchymal transition, and immune suppression.

乳腺癌中FAP基因表达的空间分析。
成纤维细胞活化蛋白(FAP)是癌症相关成纤维细胞(CAFs)的关键标志物,是癌症治疗的一个有前景的靶点。然而,它在基质细胞和肿瘤细胞中的表达使治疗策略复杂化。方法:本研究采用空间转录组学方法分析了FAP基因在腔内乳腺癌中的表达模式,揭示了FAP+基质细胞、FAP+肿瘤细胞和FAP+基质近端肿瘤细胞中不同的分子特征。结果:FAP+基质细胞表现出细胞外基质(ECM)重塑基因(COL1A1、MMP2、TIMP2)、分泌因子(CXCL12、POSTN)和免疫调节剂(CD276)的上调,证实了它们在结缔组织形成和免疫抑制中的作用。相比之下,FAP+肿瘤细胞的转录变化有限,但POSTN、CD24和EPCAM升高,提示FAP在免疫逃避和上皮可塑性中起作用。讨论:空间分析显示,FAP+基质700 μm内的肿瘤细胞表现出侵袭性表型,其特征是ECM降解(MMP14, COL6A1),间充质标志物(VIM)和免疫抑制(HLA-DRA, CD276)。相反,远端肿瘤细胞表现出代谢适应(ACADSB, SCD)和生存机制(SQSTM1, NUPR1),可能会对治疗产生耐药性。结论:这项空间转录组学研究阐明了FAP在腔内乳腺癌中的复杂和环境依赖性作用,揭示了由其细胞来源和空间位置驱动的独特分子程序。我们证明,FAP+ CAFs是深度免疫抑制和促纤维化肿瘤微环境的主要构建者,其特征是广泛的ECM重塑和CXCL12和CD276的分泌。此外,我们发现了一种新的侵袭性肿瘤细胞亚群,它与FAP+基质接近,表现出具有ECM降解、间质转化和免疫抑制特征的杂交表型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current cancer drug targets
Current cancer drug targets 医学-肿瘤学
CiteScore
5.40
自引率
0.00%
发文量
105
审稿时长
1 months
期刊介绍: Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书